#332 A Jab for Your CAD: Influenza vaccination for the prevention of cardiovascular events
CLINICAL QUESTION
Does influenza vaccination reduce the risk of cardiovascular events?
BOTTOM LINE
For every 100 patients vaccinated for influenza within about one month after an acute coronary syndrome, there will be 2 fewer cardiovascular events and 2 fewer deaths at one year compared to placebo. The impact of influenza vaccination in primary cardiovascular prevention and other cardiovascular conditions is less clear.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Five meta-analyses1-5 compared the effect of influenza vaccination to placebo/no vaccination on cardiovascular events (5-8 randomized controlled trials [RCTs], 4,211-12,029 patients, follow-up 1.5-12 months). Focusing on the most complete (results statistically significant unless otherwise stated):
- Secondary prevention:
- Influenza vaccination reduced the risk of all-cause mortality (relative risk reduction [RRR] 42%) and cardiovascular events (RRR 37%).1
- Largest, highest-quality, multi-country (mostly European) RCT6 compared one-time influenza vaccination to placebo in 2,532 participants ≤3 days after myocardial infarction. At 1 year:
- Death: 2.9% versus 4.9% with placebo.
- Cardiovascular events (death, myocardial infarction, stent thrombosis): 5.3% versus 7.2% with placebo.
- Local injection site reactions: ~5% absolute increase.
- Largest, highest-quality, multi-country (mostly European) RCT6 compared one-time influenza vaccination to placebo in 2,532 participants ≤3 days after myocardial infarction. At 1 year:
- Limitations: Cardiovascular benefit only seen in patients within <2 months of acute coronary syndrome (unclear benefit in chronic coronary artery disease) in subgroup analysis.2
- Influenza vaccination reduced the risk of all-cause mortality (relative risk reduction [RRR] 42%) and cardiovascular events (RRR 37%).1
- Other cardiovascular disease:7
- Influenza vaccine did not reduce death or cardiovascular events in 2-year RCT of 5,129 patients with heart failure when compared to placebo but reduced overall hospitalization (15% versus 18% with placebo).
- Primary prevention:3
- No difference in cardiovascular deaths based on 12 events in 2 RCTs.
- No other cardiovascular events reported.
- No difference in cardiovascular events between: Different vaccine types/dose;8 or timing (administration during myocardial infarction hospitalization or within 30 days of discharge).9
CONTEXT
- Recent respiratory tract infections/influenza are associated with increased risk of cardiovascular events.10-11
- Guidelines recommend influenza vaccination for people with coronary disease.12
- ~40% of Canadian adults with a chronic condition receive influenza vaccination each year.13
- Influenza vaccine efficacy for secondary cardiovascular prevention is comparable to other preventive therapies in reducing recurrent cardiovascular events [examples: Acetylsalicylic acid and statins (RRR ~25%)].14,15
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
this article confirmed my understanding of flu vax benefit and CV risk from influenza illness
subgroup analysis which sometimes creates bias, however good message is still vaccinating post MI is still beneficial
great support for advising to immunize!
Influenza vaccine reduces major Cv events within first year after acute coronary syndrome
the benefit equates to giving clopidogrel after MI , wth less harms !